Fig 1: Samples at diagnosis of the 50 AML patients with maximum values (TOP50: 700–1,400 G/L) of excess platelet rebound (EPR) were compared to the 50 patients with the lowest maximum number of platelets (BOT50: 10–120 G/L) after induction chemotherapy cycle 1. (A) Thrombopoietin (TPO) was assessed in the plasma by ELISA, and MPL protein was determined using lysates from leukemic blasts. Peripheral blood from healthy volunteers is shown as a control. (B) mRNA expression using lysates from leukemic blasts at diagnosis in the two patient subgroups are presented as dCt values. The median dCt values are not significantly different for MPL gene expression, but they differ significantly for KLF4, MYB, NF1A and NFE2. There are no significant differences for GATA1 and GATA2 gene expression.
Supplier Page from Aviva Systems Biology for MPL ELISA Kit (Human) (OKCD07412)